Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.
Follow-Up Questions
Shanghai Henlius Biotech Inc のCEOは誰ですか？
Mr. Jun Zhu は Shanghai Henlius Biotech Inc の Chief Executive Officer で、2021 から在籍しています。
SGBCF の株価パフォーマンスは？
SGBCF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Shanghai Henlius Biotech Inc の主な事業テーマや業界は？
Shanghai Henlius Biotech Inc は Biotechnology 業界、セクターは Health Care に属しています。
